Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction

US9439979B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• John A. Chiorini · Silver Spring, US
• Melodie L. Weller · Silver Spring, US
• Michael Schmidt · Kensington, US

Key dates

• Filing date: Jun 11, 2014
• Grant date: Sep 13, 2016
• Expiry date: Jun 14, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14145
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.